LMRI (Lumexa Imaging Holdings) YoY EBITDA Growth: 13.40% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LMRI Lumexa Imaging Holdings Inc LMRI
9 GF Score
Price $12.26
! 2 Warning Signs
View Full Analysis

What is Lumexa Imaging Holdings YoY EBITDA Growth?

Lumexa Imaging Holdings LMRI +4.70% 9 YoY EBITDA Growth is 13.40% as of Mar. 2026. GuruFocus rates LMRI with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Lumexa Imaging Holdings's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 13.40%.

Lumexa Imaging Holdings's EBITDA per Share for the three months ended in Mar. 2026 was $0.35.

Lumexa Imaging Holdings YoY EBITDA Growth Related Terms

Lumexa Imaging Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Lumexa Imaging Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumexa Imaging Holdings YoY EBITDA Growth Chart

Lumexa Imaging Holdings Annual Data
Trend Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -11.53 65.73

Lumexa Imaging Holdings Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 13.40
LMRI
9GF Score
Lumexa Imaging Holdings Inc LMRI
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumexa Imaging Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Lumexa Imaging Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(1.997-1.205)/ | 1.205 |
=65.73 %

Lumexa Imaging Holdings's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.347-0.306)/ | 0.306 |
=13.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 13.40% mean?
Lumexa Imaging Holdings (LMRI) has a YoY EBITDA Growth of 13.40% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Lumexa Imaging Holdings and its competitors.
Is Lumexa Imaging Holdings' YoY EBITDA Growth too high?
Lumexa Imaging Holdings' current YoY EBITDA Growth is 13.40%. Overall, Lumexa Imaging Holdings has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Lumexa Imaging Holdings' YoY EBITDA Growth compare to QDEL and PRCT?
Lumexa Imaging Holdings' YoY EBITDA Growth of 13.40% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Lumexa Imaging Holdings and its competitors. Lumexa Imaging Holdings's current YoY EBITDA Growth is 13.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumexa Imaging Holdings stock overvalued right now?
Lumexa Imaging Holdings (LMRI) has a current YoY EBITDA Growth of 13.40%. The current YoY EBITDA Growth is 13.40%. Lumexa Imaging Holdings' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Lumexa Imaging Holdings (LMRI), the current YoY EBITDA Growth is 13.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumexa Imaging Holdings Business Description

Address 4200 Six Forks Road, Suite 1000, Raleigh, NC, USA, 27609
Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.
9GF Score

Get the complete analysis for LMRI

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.26
Price